News

The FDA files the NDA for Axsome’s AXS-12 for cataplexy in narcolepsy, backed by phase 3 data wins showing fewer attacks and better daytime alertness.

The assistant professor in the Department of Behavioral Science at the University of Kentucky discusses a nonpharmacologic intervention designed to address sensory processing impairments in older adults with dementia. [WATCH TIME: 5 minutes]

At AAIC 2026, the senior research professor of neurology at Indiana University School of Medicine discussed the evolving role of blood-based Alzheimer disease biomarkers, particularly p-tau217.

At AAIC 2026, professor of neurology at Washington University in St. Louis discussed how integrating clinical assessment with amyloid biomarkers can improve diagnostic accuracy in Alzheimer disease. [WATCH TIME: 5 minutes]

The 60 mg dose showed the largest treatment effect, slowing decline by 26% on CDR-SB, 42% on ADAS-Cog13, and 50% on MMSE at 18 months, while all doses produced 50% to 65% reductions in CSF total tau and unprecedented tau PET reductions across brain regions.

At AAIC 2026, associate professor of neurology at Albert Einstein College of Medicine discussed a culinary medicine intervention to improve MIND diet adherence and mood in older adults with type 2 diabetes. [WATCH TIME: 5 minutes]

MCLENA-1 enrolled only 6 completers due to funding constraints but demonstrated 12 months of continuous lenalidomide was safe and tolerable, with nonsignificant trends favoring treatment on cognition and global outcomes.

In a single-center retrospective analysis, approximately two-thirds of patients with treatment-refractory headache disorders reported improvement with off-label suzetrigine, supporting further prospective evaluation of the selective NaV1.8 inhibitor.

A new phase 2 trial, presented at AAIC 2026, aims to evaluate the effects of urolithin A on mitophagy/autophagy activity, oxidative stress, multi-omic profiling, and cognitive function in APOE4 carriers.

The APPLAUDS trial will evaluate mivelsiran, an intrathecally delivered siRNA targeting amyloid precursor protein, in cognitively stable adults aged 40 to 55 with early-stage Down syndrome and early-stage Alzheimer disease who have elevated amyloid burden.

In the largest study of its kind, researchers examined the potential neurological effects of repetitive head impacts in retired elite soccer players, with findings offering new insights into symptoms, brain structure, and future research directions. [WATCH TIME: 3 Minutes]

Post hoc analyses from the phase 3 GRADUATE program suggest higher baseline tau pathology may limit amyloid removal with gantenerumab, offering new insight into factors that could influence response to anti-amyloid therapy.

Leslie M. Thompson, PhD; Ravi Rajmohan, MD, and Jefferson W. Chen, MD, from UCI Health discuss the rationale, delivery, and early steps of REGEN4HD, the world's first neural stem cell phase 1b/2a clinical trial for Huntington disease.

In a prespecified analysis presented at AAIC 2026, findings showed that plasma p-tau217 declined from baseline in valiltramiprosate-treated MCI patients compared with placebo over 78 weeks.

Here's some of what is coming soon to NeurologyLive® this week.

In a cross-sectional analysis of more than 1700 participants, plasma CGRP concentrations did not distinguish individuals with migraine from healthy controls, suggesting limited utility as a standalone diagnostic biomarker.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is RNA-targeted therapeutics

The director of the Division of Neuroscience at IRCCS Istituto Ortopedico Rizzoli discusses why targeting shared biologic pathways, rather than individual mutations, may represent a promising therapeutic strategy for Charcot-Marie-Tooth disease. [WATCH TIME: 2 minutes]

An Oxford study found that current smokers with MOGAD had a 2.2-times higher annualized relapse rate than never smokers, whereas past smokers showed no elevated risk, supporting smoking cessation as a modifiable management target.

Neurology News Network for the week ending July 11th, 2026. [WATCH TIME: 4 minutes]

Ahead of the 2026 Alzheimer's Association International Conference, David Wolk, MD, discusses the meeting's biggest scientific themes, from plasma biomarkers and disease-modifying therapies to emerging technologies and evolving clinical practice.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 10, 2026.

Recent findings from a study of growth and nutritional status in primary ciliary dyskinesia revealed high rates of undernutrition, obesity, and vitamin D insufficiency across pediatric and adult populations.

Carol Rosen, MD, professor emerita of pediatrics at Case Western Reserve University School of Medicine, discussed the transformation of pediatric sleep medicine from a clinical curiosity to a core medical specialty at SLEEP 2026.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Daniel Ontaneda, MD, PhD. [LISTEN TIME: 20 minutes]

The first randomized, double-blind trial directly comparing the 2 anti-CD20 agents showed rituximab met the prespecified noninferiority criterion on MRI suppression, with a similar serious adverse event profile and a substantially lower cost.

AbobotulinumtoxinA met its primary end point in both the E-BEOND and C-BEOND phase 3 trials, marking the first time a botulinum toxin has demonstrated statistically significant efficacy in episodic migraine prevention.

Fariha Abbasi-Feinberg, MD, FAASM, FAAN, newly installed president of the American Academy of Sleep Medicine and medical director of sleep medicine at Millennium Physician Group, shares her clinical and policy priorities for the year ahead and her vision for the future of sleep medicine.